Hepatocellular carcinomas (HCCs) exhibit a diversity of molecular phenotypes, raising major challenges in clinical management. HCCs detected by surveillance programs at an early stage are candidates for potentially curative therapies (local ablation, resection, or transplantation). In the long term, transplantation provides the lowest recurrence rates. Treatment allocation is based on tumor number, size, vascular invasion, performance status, functional liver reserve, and the prediction of early (<2 years) recurrence, which reflects the intrinsic aggressiveness of the tumor. Well-differentiated, potentially low-aggressiveness tumors form the heterogeneous molecular class of nonproliferative HCCs, characterized by an approximate 50% b-catenin mutation rate. To define the clinical, pathological, and molecular features and the outcome of nonproliferative HCCs, we constructed a 1,133-HCC transcriptomic metadata set and validated findings in a publically available 210-HCC RNA sequencing set. We show that nonproliferative HCCs preserve the zonation program that distributes metabolic functions along the portocentral axis in normal liver. More precisely, we identified two well-differentiated, nonproliferation subclasses, namely periportal-type (wild-type b-catenin) and perivenous-type (mutant b-catenin), which expressed negatively correlated gene networks. The new periportal-type subclass represented 29% of all HCCs; expressed a hepatocyte nuclear factor 4A-driven gene network, which was downregulated in mouse hepatocyte nuclear factor 4A knockout mice; were early-stage tumors by Barcelona Clinic Liver Cancer, Cancer of the Liver Italian Program, and tumor-node-metastasis staging systems; had no macrovascular invasion; and showed the lowest metastasis-specific gene expression levels and TP53 mutation rates. Also, we identified an eight-gene periportal-type HCC signature, which was independently associated with the highest 2-year recurrence-free survival by multivariate analyses in two independent cohorts of 247 and 210 patients. Conclusion: Well-differentiated HCCs display mutually exclusive periportal or perivenous zonation programs. Among all HCCs, periportal-type tumors have the lowest intrinsic potential for early recurrence after curative resection. (HEPATOLOGY 2017;66:1502-1518.
H epatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. HCC is endemic in East Asia and sub-Saharan Africa, and its incidence has doubled over the past 20 years in Western countries. Projections anticipate a further increase in incidence, despite recent breakthroughs in the management of chronic hepatitis.
(1) More than 80% of HCCs arise in a field of
Abbreviations: AFP, alpha-fetoprotein; CTNNB1, b-catenin; ECM, extracellular matrix; GLUL, glutamate ammonia ligase; HAL, histidine ammonia lyase; HCC, hepatocellular carcinoma; HNF4A, hepatocyte nuclear factor 4A; KO, knockout; LGR5, leucine-rich repeat containing G protein-coupled receptor 5; ODAM, odontogenic ameloblast-associated protein; PP, periportal; PV, perivenous; RNAseq, RNA sequencing; STEM, stem cell features; TCGA, The Cancer Genome Atlas; VNN1, vanin 1. chronic liver disease resulting from viral hepatitis, alcohol, hemochromatosis, obesity, and metabolic syndrome or genotoxins. This diversity in etiology and natural history results in high HCC heterogeneity, raising major challenges in clinical management. (1) Current therapeutic strategies are based upon tumor number, size, vascular invasion, performance status, and functional reserve of the liver. These variables have been integrated in the Barcelona Clinic Liver Cancer classification to match the best candidates with the best therapies available.
(1) Surveillance programs currently detect early-stage tumors (single or 3 or fewer nodules 3 cm) that are candidates for potentially curative therapies (local ablation, resection, or transplantation) with 5-year survival rates of 50%-70%. Five-year recurrence rates after HCC resection (up to 70%) or even higher after percutaneous ablation make liver transplantation the best possible treatment, with a recurrence rate of 10% and the additional advantage of eliminating the underlying liver disease.
(1) Treatment allocation for early-stage HCCs might be improved by identifying homogeneous molecular subclasses with predictable outcomes. (2, 3) The molecular landscape of HCCs is emerging as a result of global gene expression analyses and the discovery of crucial driver tumor mutations. (1, 2) At present, HCCs are split into two molecular classes, each representing 50% of tumors: proliferative and nonproliferative HCCs. (2) Proliferative HCCs include two subclasses enriched in WNT/transforming growth factor beta signals and stem/progenitor cell markers, respectively.
(1,2) Among nonproliferative HCCs, half of the tumors form a homogeneous subclass with a high rate of activating b-catenin (CTNNB1) exon 3 mutations. (2, (4) (5) (6) These tumors are well differentiated, (2, (4) (5) (6) (7) (8) but patient survival rates do not differ from HCCs carrying wild-type CTNNB1 (reviewed in Supporting Table S1 ). The rest of the nonproliferative HCCs carry wild-type CTNNB1, (5) but no evidence to date allowed them to qualify as a homogeneous HCC subclass.
This study was conducted to determine whether nonproliferative HCCs carrying wild-type CTNNB1 warrant consideration as a distinct, clinically relevant tumor subclass. To analyze a large and statistically powerful population, we constructed a 1,133-HCC transcriptomic metadata set and identified four HCC subclasses by discriminant analyses and hierarchical clustering. As the 1,133 HCCs were not annotated for CTNNB1 mutations, we developed a reliable method to predict CTNNB1 mutations in an independent set of 225 bcatenin-sequenced HCCs. CTNNB1 mutation prediction, HCC classification, and survival analyses were further validated in an external RNA sequencing (RNAseq) data set of 210 HCC patients (Fig. 1) .
Altogether, analysis of data from 1,568 HCC patients identified two new well-differentiated, mutually exclusive, low-proliferation subclasses of HCCs. Both subclasses showed favorable outcomes and preserved metabolic liver zonation programs. They respectively displayed periportal (PP; wild-type b-catenin) or perivenous (PV; mutant b-catenin) phenotypes. PPtype HCCs showed the highest 2-year recurrence-free survival rates by multivariate analysis, suggesting that these tumors have the lowest potential for early recurrence among all HCCs.
FIG. 1.
Flowchart of the study. (A) Construction of a transcriptomic metadata set for subclass-specific analyses after curative resection of 1,133 HCCs. Nine public transcriptomic data sets (A-I) were merged into a metadata set. As the 1,133 HCCs were not annotated for CTNNB1 mutations, we developed a CTNNB1 mutation prediction score from transcriptomic data. The most stable markers were identified by sparse partial least squares discriminant analysis modeling in training and validation sets. Mutation prediction was validated in an external in-house HCC collection (9) ; then, CTNNB1 mutations were predicted in 1,133 HCCs after cross-platform normalization. Subclass-specific survival analyses were performed in data set C (n 5 247 HCCs) (34) and validated in an external RNAseq, full genome-sequenced data set (LIHC-US; TCGA consortium, n 5 210 HCCs). (10) (B) Transcriptomic data sets used: 1, yes or present; 0, no or absent. References: training set (4) ; validation set (6) ; A (44) ; B (45) ; C (34) ; D (46) ; E (47) ; F (48) ; G (49) ; H (49) ; I (28) ; RNAseq data set. (10) Major endpoints are indicated by bold arrows. External validation sets are represented by black boxes. Abbreviation: sPLS-DA, sparse partial least squares discriminant analysis.
Patients and Methods

PATIENTS, STUDY DESIGN, AND DATA MANAGEMENT
The study design is presented in Fig. 1 . Nine public transcriptomic data sets passing the quality control analyses were integrated into a metadata set totaling 1,133 HCCs and 9,542 genes (Supporting Tables S2  and S3 ). As HCCs in these data sets were not annotated for CTNNB1 mutations, we developed a robust prediction method. Complying with REMARK guidelines, identification of CTNNB1 mutation predictors in a training set (n 5 87) was confirmed in a validation set (n 5 56) and in our recently described in-house independent cohort (n 5 82). (9) The three data sets (Supporting Table S2 ) were annotated for Sanger-sequenced CTNNB1 exon 3 mutations (Supporting Table S4 ). We thus predicted CTNNB1 mutational status in the 1,133-HCC transcriptomic metadata set. Independently, hierarchical cluster analysis was used in this metadata set to identify robust HCC subclasses. Then, the resulting tumor classification was validated in a 210-HCC patient data set from The Cancer Genome Atlas (TCGA) consortium (10) (normalized RNAseq genome-wide mRNA expression, whole-genome sequencing, and clinical data downloaded in June 2016 from the TCGA website). Out of 294 HCCs with available RNAseq and clinical annotations, 84 met our exclusion criteria (Supporting Fig. S1A ). Quality control of clinical annotations was performed by studying the relationship between tumor staging and overall/disease-free survival by KaplanMeier plots and log rank tests (Supporting Fig. S1B ).
Raw data from publically available transcriptome profiling experiments were extracted from Gene Expression Omnibus. Probes detected over background in at least one HCC were quantile-normalized (R package preprocessCore), log 2 intensity expression values for each probe set were calculated by robust multiarray average cross-platform, and batchdependent variances were corrected with COM-BAT (11) (R package sva) in the 1,133-HCC metadata set and with YuGene (12) (R package YuGene) in the data sets used for CTNNB1 mutation prediction.
STATISTICAL ANALYSES
To optimize the identification of stable gene predictors of CTNNB1 activating mutations, we applied sparse partial least squares discriminant analysis with bootstrap subsampling (Supporting Fig. S2 ), as described. (13) After further marker validation in the inhouse cohort by real-time PCR, we established a score to predict CTNNB1 mutations. Independently, robust HCC subclasses were identified using hierarchical cluster analysis defined by a stepwise algorithm (see Supporting Information). Survival analyses were performed using the log rank test, Kaplan-Meier curves, and Cox models. Statistical analyses were performed with R (version 3.3.0).
See Supporting Information for tissue banking, fully detailed statistics, functional genomics, detection of bcatenin exon 3 mutations/deletions, tissue microarraybased immunohistochemistry, antibodies, cell culture, nucleic acid extraction, real-time PCR, primers, and RNA interference.
Results
A ROBUST FIVE-GENE SCORE PREDICTS CTNNB1 MUTATIONS IN LARGE TRANSCRIPTOMIC DATA SETS
As described in the Patients and Methods section and Fig. 1 , nine public transcriptomic data sets were integrated into a metadata set of 1,133 HCCs and 9,542 genes (Supporting Tables S2 and S3 ). The 1,133-HCC transcriptomic data set was not annotated for CTNNB1 mutational status; thus, we set up a robust pipeline to predict CTNNB1 activating mutations (Fig. 1) . The model achieved a prediction accuracy of 87% in the training set and 93% in the independent validation sets (Supporting Fig. S2 ). The analysis identified histidine ammonia-lyase (HAL) and vanin 1 (VNN1) (selected in >85% of the models after 300 bootstrap runs), which were both down-regulated in HCCs carrying mutant CTNNB1. In addition, a search for the top up-regulated genes in HCCs carrying CTNNB1 mutations identified odontogenic ameloblast-associated protein (ODAM). Then, to construct a score predicting CTNNB1 mutations, we combined HAL, VNN1, and ODAM with two well-known markers of CTNNB1 activating mutations in HCCs: glutamate ammonia ligase (GLUL) and leucine-rich repeat containing G protein-coupled receptor 5 (LGR5). (14) RNA expression levels of the five biomarkers were significantly associated with mutant CTNNB1 in the three data sets ( Fig. 2A,B) . AXIN2, which reflects Wnt/b-catenin pathway activation, (15) FIG. 2. A five-gene score reliably predicts CTNNB1 mutations using mRNA expression data in HCCs. (A) Gene expression of the five biomarkers in the training (n 5 87), validation (n 5 56), and external validation (n 5 82) sets, according to Sanger-sequenced CTNNB1 mutational status. AXIN2 was included as a Wnt pathway activation marker (missing in A2). (B) Heatmaps showing mRNA expression of the five biomarkers plus AXIN2 and CTNNB1 mutational status (B1, training set; B2, validation set; B3, external HCC collection). Low and high gene expressions (median as cutoff) are represented in green and red, respectively. (C) Formula; (D) performance, and (E) receiver operating characteristic curves of the CTNNB1 mutation prediction score. (F) Tissue microarraybased immunostaining (brown) for GLUL, HAL, and VNN1 in 20 CTNNB1 mutant and 20 CTNNB1 wild-type HCCs. Insets on the right: b-catenin cell membrane staining in CTNNB1 wild-type (arrowheads, upper right) or cytoplasmic and nuclear staining in CTNNB1 mutant HCCs (arrowheads, lower right). (G) Immunostaining (brown) for ODAM and GLUL in serial sections in a CTNNB1 mutant HCC. Images were acquired with a tissue slide scanner at 320 original magnification. *P < 0.05, **P < 0.01, ***P < 0.001 (Wilcoxon tests). Abbreviations: AUROC, area under the receiver operating characteristic curve; CI, confidence interval; MUT, mutant; qPCR, quantitative real-time PCR (a pool of five normal liver samples was used as calibrator); WT, wild type.
was positively correlated with GLUL, LGR5, and ODAM and negatively correlated with HAL and VNN1 ( Fig. 2A,B ; Supporting Fig. S3A ). Cluster analyses confirmed the association of the five markers with CTNNB1 mutation (Fig. 2B1-B3 ). In the external validation set, CTNNB1 mutation was negatively associated with invasive (gamma 5 20.83, P < 10-3) and multinodular (gamma 5 20.56, P 5 0.02) tumors (Fig. 2B3 ). In turn, nuclear b-catenin immunostaining was positively correlated with CTNNB1 mutations, GLUL, ODAM, and LGR5 and negatively with VNN1 and HAL (Supporting Fig. S3B ). Combination of the five markers into an arithmetic score resulted in a reliable prediction in the three data sets (area under the receiver operating characteristic curve 5 0.87-0.90, sensitivity 5 0.86-0.91, specificity 5 0.83-1; Fig. 
2C-E).
Tissue microarray-based immunohistochemistry in 20 HCCs carrying mutant versus 20 HCCs carrying wild-type CTNNB1 revealed a clear-cut difference in GLUL expression between HCCs showing mutant and wild-type CTNNB1 at low-power microscopic examination, whereas HAL and VNN1 were globally higher in wild-type samples (Fig. 2F ). ODAM protein expression was low in all samples (not shown) but detected in HCCs carrying mutant CTNNB1 and expressing high GLUL (Fig. 2G ).
In the external validation set, analysis of matching HCC and nontumor samples showed that tumor/nontumor ratios were highly predictive of CTNNB1 mutations (area under the receiver operating characteristic curve 5 0.90, sensitivity 5 0.87; specificity 5 0.88) (Supporting Fig. S3C-F ). As data from nontumor tissues were not available in all the transcriptomic data sets, further predictions of CTNNB1 mutations were performed with tumor samples. Thus, we predicted CTNNB1 mutations in the 1,133 HCCs of the metadata set (Supporting Table S5 ). Predicted mutation rates of 20%-40% matched the described CTNNB1 mutation rates in HCC. (16) To better understand the association of the newly discovered biomarkers (HAL, VNN1, and ODAM) with CTNNB1 activating mutations, we analyzed human HCC cell lines (Supporting Fig. S4 ). HAL was expressed at higher levels in HCC cell lines carrying wild-type CTNNB1, i.e., Huh7 or HepaRG, than in those carrying activating CTNNB1 mutations, i.e., B16, BC2, HepG2, and Huh-6. VNN1 was expressed at much higher levels in HepaRG cells than in the cell lines carrying mutant CTNNB1. By contrast, Huh7 expressed VNN1 at low levels. Last, ODAM was clearly expressed at higher levels in cell lines carrying mutant than in those carrying wild-type CTNNB1. The glycogen synthase kinase 3b inhibitor 6-bromoindirubin-3 0 -oxime, which activates b-catenin signaling, (17) strongly up-regulated b-catenin-dependent transcriptional activity (Supporting Fig. S5A ). 6-Bromoindirubin-3 0 -oxime up-regulated GLUL, LGR5, and ODAM (Supporting Fig. S5B ) and attenuated the increase in hepatocyte nuclear factor 4A (HNF4A), ALDOB, HAL, and VNN1 mRNA expression over the 30 days required for differentiation of HepaRG progenitors to hepatocyte-like cells (Supporting Fig. S5C-F) . Conversely, HepaRG cells transfected with b-catenin targeting small interfering RNA down-regulated AXIN2 and ODAM and up-regulated HAL and VNN1 mRNA expression (Supporting Fig. S5G ). In addition, in silico analysis of the 5,000 base pairs upstream of the transcription start site of ODAM DNA (NM_017855; PROMO program, (18) TRANSFAC database) revealed three putative T-cell factor 4/LEF-1 consensus transcription factor binding sites in the ODAM 5 0 -untranslated region at positions -99, -1262, and -3956. Taken together, these data suggest that b-catenin signaling regulates HAL, VNN1, and ODAM mRNA expression.
PREDICTED CTNNB1 MUTATIONS CLUSTER WITHIN A HOMOGENEOUS TUMOR SUBCLASS AFTER ANALYSIS OF TRANSCRIPTOMIC DATA FROM 1,343 HCCs
We integrated the nine data sets into a 1,133-HCC metadata set with 9,542 common genes and performed cross-platform normalization with the COMBAT algorithm (11) (Supporting Fig. S6 ). Identification of the 1,618 most discriminant genes by partial least squares discriminant analysis, using a variable importance in the projection score threshold >1, followed by stepwise hierarchical cluster analysis, identified four subclasses. Subclasses were named red, green, blue, and purple before further functional characterization (Supporting Fig. S7 ). The red subclass had a predicted CTNNB1 mutation rate of 84% (Supporting Fig. S7 ). The predicted CTNNB1 mutation rates in this subclass were high in all data sets (65%-100%; Supporting Table S6 ). These findings are consistent with evidence that HCCs carrying CTNNB1 mutation are a homogeneous subclass. (4, 6) Reproducibility (Supporting Fig. S8 ) and robustness (Supporting Fig. S9A,B) analyses showed that the red and green subclasses had similarly low intracluster inertia, indicating high homogeneity of HCC samples within each cluster. In terms of gene expression profiles, the purple cluster was highly different from the red and green ones, whereas the blue cluster was intermediate between the green and purple ones (Supporting Fig. S9C ). To further test the robustness of the HCC classification, we repeated partial least squares discriminant analysis-based identification of the most discriminant genes with a more stringent variable importance in the projection score threshold (>1.5), which yielded 550 top discriminant genes and confirmed the four tumor subclasses (Supporting Fig.  S9D ). Further, the value of the 550-gene set as a classifier was confirmed in the external validation RNAseq data set (n 5 210 HCCs; Supporting Fig. S9E ). Thus, using the top 550 genes, both the 1,133-HCC transcriptomic (Fig. 3A) and the 210-HCC RNAseq (Supporting Fig. S9E ) data sets confirmed four HCC subclasses and three gene sets. In the red subclass, CTNNB1 was predicted to be mutated in 89% of HCCs (Fig. 3A) . Consistent with the high rate of predicted CTNNB1 mutations, the red subclass showed the highest levels of GLUL, LGR5, and ODAM and the lowest levels of VNN1 and HAL (Fig. 3B) .
By immunohistochemistry in human liver (Fig.  3C,D) , GLUL showed a clear perivenous localization, as expected. (19) HAL showed a clear-cut periportal distribution, consistent with its expression by periportal hepatocytes in mice. (20) VNN1 was panlobular and abundantly detected in the cytoplasm and in bile canaliculi in normal liver and in well-differentiated HCCs (Fig. 3C,D) , which goes well with the evidence that VNN1 is one of the 59 major proteins in human bile. (21) Further, anti-VNN1 staining of bile canaliculi was totally suppressed by the immunogen polypeptide (Fig. 3D) . Consistent with the above findings, fullgenome sequencing data from the independent RNAseq 210-HCC TCGA data set confirmed that 81% of HCCs within the red subclass carried CTNNB1 mutations (Supporting Fig. S9E ).
WELL-DIFFERENTIATED HCCs DISPLAY A PRESERVED METABOLIC LIVER ZONATION PROGRAM
Functional genomics studies by gene set enrichment analysis ( Fig. 4 ; Supporting Table S7) revealed that the HCC subclass containing the highest rate of predicted CTNNB1 mutations (84%) was enriched in signatures of HCCs carrying mutant CTNNB1, such as the G6 (6) and the CTNNB1 (4) subclasses, as well as perivenous hepatocyte signatures, such as fatty acid and bile salt metabolism. (20) We thus called this subclass perivenous-type HCCs (PV). The HCC subclass enriched in signatures of differentiated periportal hepatocytes (gluconeogenesis, amino acid catabolism, HNF4A-induced genes), (20) good prognosis (hepatocyte-like [S3] subclass HCCs), (5) and low recurrence (5, 22) was called periportal-type HCCs (PP). Both PP and PV subclasses were enriched in signatures of favorable survival (23) and low proliferation in HCCs. (4) The HCC subclass featuring signatures of cancer extracellular matrix (ECM) remodeling and epithelial mesenchymal transition (24) was called ECM-type HCCs. It was characterized by integrin cell-surface interactions, KRAS, TGFB, IL6, and the MMP14 network typical of invasive tumors. The last HCC subclass was associated with high-grade metastasis signatures, tumor aggressiveness with decreased patient survival, (23) the cancer stem cell program predicting metastasis and death, (25) and up-regulation of p53 mutation markers (Supporting Fig. S10 ). It was also enriched in signatures of cell cycle progression (MYC, RAC, AURKA, RB1, and PDGFRB pathways), HCCs displaying stem cell features, (26) and extrahepatic undifferentiated cancers of various origins, as well as cancer cell resistance to doxorubicin and vincristine. Thus, we called this subclass STEM-type HCCs. Both ECM-type and STEM-type HCCs shared signatures of high tumor cell proliferation (4) and were associated with the Wnt/transforming growth factor beta (S1) HCC subclass, (5) indicating bad prognosis. (27) Also, they were both associated with early recurrence. (28) Expression levels of representative genes in HCC subclasses and in gene clusters are illustrated in Fig. 4B and in Supporting Fig. S11 , respectively. Functional genomics findings were confirmed by gene ontology analysis of gene clusters (Supporting Table S8 ). The mean 6 95% confidence interval mRNA expression level of the top 550 genes in the four HCC subclasses is shown in Supporting  Table S9 .
We observed differences in the percentage of samples in each subclass according to the data set of origin (Supporting Table S10 ). The sampling technique (1,060 resections versus 73 biopsy specimens) had no impact on tumor classification (Supporting Table  S11 ). By contrast, cohorts containing >95% hepatitis C virus-positive HCCs showed a higher rate of PV ), in agreement with the well-known positive association of CTNNB1 mutation with hepatitis C virus and its negative association with hepatitis B virus. (2) THE METABOLIC PROGRAM OF PP HCCs IS REGULATED BY HNF4A
The interplay between T-cell factor 4, b-catenin, and HNF4A (20) governs the differential distribution of metabolic liver functions along the portocentral axis of the liver, which is known as liver zonation. (29) Using the ortholog genes of the mouse liver PP and PV signatures, (20) we clustered the 326 PP and the 210 PV HCCs from the 1,133 HCC metadata set. We observed a remarkable matching of mouse normal liver perivenous genes with PV HCCs and mouse normal liver periportal genes with PP HCCs, thus confirming the identity of both HCC subclasses described above (Supporting Fig. S12A ). Subsequently, network analysis in the 1,133 patient metadata set revealed that periportal and perivenous genes were negatively correlated and respectively upregulated in PP and PV HCCs (Fig. 5A) . Predictive markers of CTNNB1 mutation showed high connectivity within this network. GLUL, HAL, and LGR5 were connected respectively with 60 (42%), 54 (38%), and 54 (38%) of the genes in the network, respectively. Although mouse Odam and Vnn1 were not present in the original periportal and perivenous signatures, (20) human ODAM and VNN1 were connected, respectively, with 47 (33%) and 28 (20%) of the genes in human HCCs.
Suppression of HNF4A in mouse liver has profound effects on zonated metabolic functions, (30, 31) cell proliferation, (30) and oncogenesis. (32, 33) Consistent with this, the top 550 genes representative of the four HCC subclasses perfectly discriminated Hnf4a knockout (KO) and Hnf4a-wild type (31) mouse livers (Fig. 5B) . Among the 550 genes, a first cluster was strongly upregulated in Hnf4a-KO mice and clearly enriched in genes up-regulated in ECM/STEM HCCs. A second cluster was down-regulated in Hnf4a-KO mice and enriched in genes up-regulated in PP HCCs. The rest of the genes (20%) were poorly affected by HNF4A. Finally, we extracted from the Hnf4a-KO data set the genes showing the highest modulation (fold-change >2 or <0.5 and Bonferroni-adjusted P < 0.01) to look at the expression of their orthologs in the 1,133-HCC metadata set (Supporting Fig. S12B ). Hierarchical clustering of these genes showed a good discrimination of the four subclasses (80% of samples correctly classified), with a strong enrichment of genes highly downregulated by Hnf4a-KO in PP HCCs. Conversely, genes highly up-regulated by Hnf4a-KO were remarkably enriched in the STEM-type HCC subclass. These findings are in line with the notion that HNF4A induces hepatocyte differentiation of cancer stem cells, suppressing hepatocyte proliferation and oncogenesis. (30, 32, 33) 
PP HCCs SHOW THE MOST FAVORABLE CLINICAL FEATURES AND THE HIGHEST EARLY (2-YEAR) DISEASE-FREE AND OVERALL SURVIVAL RATES AFTER RESECTION
Comparative analysis of the clinical outcome of the four HCC subclasses in a 247-HCC transcriptomic data set (34) (data set C; Supporting Table S2 ) revealed increasingly aggressive tumor phenotypes from PP through PV ! ECM ! STEM HCCs (Fig. 6A) . These subclasses showed a progressive increase in metastatic signature (34) rates, Cancer of the Liver Italian Program and Barcelona Clinic Liver Cancer scores, as well as serum alpha-fetoprotein (AFP) concentrations. Survival curves (Fig. 6B) showed a progressive decrease in overall and disease-free survival rates from PP through PV ! ECM ! STEM HCCs. Thus, the PP type is a well-differentiated, favorable-outcome HCC subclass carrying wild-type CTNNB1, displaying a periportal liver metabolic program, and expressing HNF4A target genes. In turn, the PV type is a welldifferentiated HCC subclass carrying mutant CTNNB1, displaying a perivenous liver metabolic program, and expressing b-catenin target genes.
The above data were further validated using an external 210-HCC RNAseq data set. Tumor aggressiveness was inferred from increasing AFP serum levels, tumor grade, tumor-node-metastasis staging, vascular invasion, TP53 mutation rates, tumor onset in younger patients (Fig. 6C) , as well as survival (Supporting Fig. S13 ). This analysis confirmed the existence of increasingly aggressive tumor phenotypes from PP through PV ! ECM ! STEM HCCs. The overall survival of PV HCCs was significantly more favorable than that of STEM HCCs in both the 247- (20) detected in 326 PP-type and 210 PV-type HCCs from the 1,133-HCC set. Node border colors (green/ red) denote PP/PV attributes of mouse genes, respectively. (20) Node core colors are proportional to the PV/PP fold-change in the HCC set (color key at lower right). Link thickness is proportional to correlation coefficients (>0.30 in all networks; blue, positive; red, negative correlation). (B) The 550 genes representative of the four HCC subclasses discriminate between Hnf4a-KO and Hnf4a-wild type mice. (31) Three gene clusters (black nodes on the left) denote 1, up-regulation in Hnf4a-KO and enrichment in human HCC STEM/ECM signatures; 2, up-regulation in Hnf4a-wild type and enrichment in HCC PP genes; 3, genes poorly affected by Hnf4a status. Red, high expression, green, low expression. Abbreviation: WT, wild type. HCC transcriptomic (Fig. 6B ) and the 210-HCC RNAseq (Supporting Fig. S13 ) data sets.
To obtain a PP-type HCC gene signature, we searched for genes meeting the following criteria: >2-fold change between the PP and the other HCC subclasses; high connectivity within the periportal gene network in HCCs (>0.30 correlation coefficient with >50% of the genes), and association with survival (P < 0.05 in 7/8 tests; Supporting Information). The resulting eight-gene PP-type HCC signature (Fig.  6D) was associated with favorable overall and diseasefree outcome in the 247-HCC transcriptomic (34) (Fig.  6E ) and in the 210-HCC RNAseq (Fig. 6F ) data sets. PP-type HCCs showed the lowest early (2-year) recurrence and the highest overall survival rates after resection among all other HCCs taken together. Univariate and multivariate survival analyses revealed that the PP-type HCC signature was independently associated with low early recurrence after HCC resection (Table 1) .
Of note, the PP-type HCC signature was predominantly expressed in normal liver, as shown by analysis of their mRNA expression levels in 84 tissues, (35, 36) from the GSE1133 microarray data set (Supporting Fig. S14A-H) . In addition, the expression levels of the eight genes constituting the signature were highly correlated (Supporting Table S12 ). These genes were expressed at higher levels in PP HCCs than in the other HCC subclasses (Fig. 6D) . The expression levels of these genes in 70 PP HCCs were closer to those detected in 232 nontumor livers than in 167 non-PP HCCs. Two of these genes (AGXT and OTC) were not significantly different in nontumor livers from PP HCCs (Supporting Fig. S15 ).
Discussion
Our study revealed that preservation of the liver zonation program is an important feature of welldifferentiated HCCs. PP HCCs showed the most favorable patient outcome in two independent cohorts of 247 and 210 patients. Further, they displayed the lowest rates of metastasis signature; (34) Barcelona Clinic Liver Cancer, Cancer of the Liver Italian Program, and tumor-node-metastasis staging; vascular invasion; and TP53 mutations. We identified an eight-gene PP-type HCC signature composed of liverenriched genes involved in periportal liver functions, such as amino acid catabolism (GLS2, AGXT, and GNMT), biliary acid transport (SLC10A1 and SCL22A7), lipid (SLC27A5) and glucose (FETUB) metabolism, as well as the urea cycle (OTC). These genes were expressed at higher levels in nontumor livers and in PP-type than in non-PP-type HCCs.
In normal liver, b-catenin is transiently activated in perivenous zones to meet homeostatic needs. (15) Therefore, turning OFF b-catenin in adult mouse liver constitutively leads to a default periportal metabolic program, with normal liver function. Conversely, turning ON b-catenin leads to liver hyperplasia, hyperammonemia, and death. (20) Considered in this context, PP HCCs preserve the default metabolic program of normal liver. Therefore, converging evidence indicates that the periportal program embodies the lowest level of aggressiveness in HCCs.
Recently, no association was detected between CTNNB1 mutations and survival in 362 HCC patients, (7) in line with data summarized in Supporting Table S1 . We confirmed these findings by analyzing two independent cohorts of 247 and 210 HCC patients (Fig. 7A) . Noteworthy, subclass-specific survival analyses in these two cohorts revealed that PPtype and PV-type HCC patients had a more favorable outcome than STEM-type HCC patients ( Fig. 6B;  Supporting Fig. S13) . Also, discriminant analysis confirmed that PV-type HCCs lie between PP-type and ECM-type HCCs in terms of aggressiveness (Fig.  7B ). This body of evidence suggests that HCCs carrying CTNNB1 mutations are moderately aggressive (Fig. 7C) . De novo expression of cancer stem/progenitor cell genes such as ODAM and LGR5 in CTNNB1-mutated HCCs goes well with the moderate aggressiveness of this tumor subclass. ODAM is a basement membrane component of the periodontal junctional epithelium secreted by ameloblasts, repressed in adult tissues, but expressed de novo in cancers. (37) LGR5, in turn, is expressed by liver stem cells or progenitors in response to stimuli calling for tissue renewal or tumor cell growth. (38) PV-type HCCs match the G6 (6) and CTNNB1 (4) subclasses that carry CTNNB1 mutations but not the S3 (5) subclass. In turn, the S3 subclass matches PPtype HCCs. Indeed, S3 HCCs are well-differentiated and hepatocyte-like, and approximately 50% of them carry CTNNB1 mutations. (5) Further, S3 HCC patients have a more favorable survival than S1 and S2 HCC patients. (27) As the main feature of S3 HCCs is preserved hepatocyte differentiation, S3 may include both PP-type and PV-type HCCs.
GLUL, HAL, and VNN1 are involved in metabolic liver zonation. HAL is an enzyme that degrades the amino acid histidine, (39) and we showed that it was restricted to periportal hepatocytes in normal liver. Likewise, PP-type HCCs expressed a host of amino acid-degrading enzymes, such as ARG1 and GLS2, which were major hubs in the periportal gene network in HCCs (Fig. 5A) . Some of these amino aciddegrading enzymes, such as SDS and GLDC, yield the end product oxaloacetate, which is used for gluconeogenesis, a periportal metabolic pathway. (20, 40) VNN1 is a key activator of hepatic gluconeogenesis, transcriptionally activated by HNF4A. (41) By immunohistochemistry, VNN1 had a panlobular distribution, consistent with unsupervised transcriptomic data, (20, 40) suggesting that VNN1 probably responds to dynamic zonation. (29) Crosstalk between HNF4A and b-catenin controls the transcription of genes involved in periportal and perivenous zonation in normal liver. (29) Our data suggest that this crosstalk is preserved in well-differentiated HCCs. The five-gene score predicting CTNNB1 mutation was composed of genes known to be up-regulated by bcatenin (LGR5, GLUL, and ODAM) or by HNF4A (VNN1 and HAL). (20, 41) By in vitro experiments, we confirmed that b-catenin activation enhanced GLUL, LGR5, and ODAM but inhibited HAL and VNN1 expression. Conversely, b-catenin knockdown silenced AXIN2 and ODAM but enhanced HAL and VNN1 expression. Further, we showed that b-catenin activation attenuated the gain in the expression of HNF4A, ALDOB, HAL, and VNN1 upon the 30-day time course of differentiation of HepaRG progenitors into hepatocyte-like cells (Supporting Fig. S5C-F) . These observations suggest that b-catenin mutations divert the default periportal metabolic program of welldifferentiated HCC cells toward a perivenous one (Fig. 7B) .
In summary, we identified a new well-differentiated HCC subclass, PP-type HCCs, which has the most favorable clinical outcome among all HCCs. Accordingly, the PP-type HCC signature was associated with low early HCC recurrence (<2 years after resection) independently of tumor size and vascular invasion in multivariate analyses. Given the heterogeneity of HCC phenotypes shown in Fig. 7B , the question arises whether early, well-differentiated HCC types (PP and PV) ultimately progress to a more aggressive, progenitor-like phenotype spontaneously or in response to treatments that may spare cancer progenitor cells.
Prediction of patient survival impacts the indication of liver transplantation for HCC. In particular, early recurrence is one of the principles governing patient staging within the spectrum of eligibility for liver transplantation. (3) Thus, it would be interesting to test whether identification of PP-type HCCs would contribute to adapting indications of liver transplantation beyond current criteria. This issue will gain importance in the near future because control of hepatitis C virus epidemics with direct antiviral agents will increase donor liver availability. The major limitation to the direct translation of these basic findings to the clinical arena is the exclusion of diagnostic liver biopsy from current guidelines for HCC diagnosis and allocation to treatments. However, in view of exciting results demonstrating the clinical relevance of metabolic imaging in early-stage HCCs (42) and of the association of the transporter of gadoxetic acid OATP1B3 with Wnt/b-catenin signaling in HCCs, (43) the PP-type molecular phenotype raises a new challenge to metabolic imaging of HCCs.
